Amneal Pharmaceuticals (AMRX): Time to Buy this HEALTHY Growth Stock

Given the recent increase in market volatility I wanted to share a Stock of the Week that fits the times. This led me to select Amneal Pharmaceuticals (AMRX). 

It makes sense now because stocks in more defensive groups generally hold up better under market volatility. So that’s a good reason to consider a healthcare stock. 

On the other hand, this is a small cap drug company with explosive upside potential. So that means it should thrive when the next bull run charges ahead. 

Let’s focus on that growth story. 

Right now they are expected to grow earnings 38% year over year. For as strong as that sounds, please remember they have averaged a 33% beat the past few quarters. So likely earnings growth will end up even higher than expected. 

One major growth catalyst has been the launch of CREXONT (for Parkinson’s disease), which management highlighted as a standout contributor. Other newer products, including injectable and complex medicines (not just plain tablets), are also gaining traction. 

All in all, the che company leverages its ability to make “complex dosage forms” — injectables, inhalants, ophthalmics, etc. — which limits competition and tends to command better margins. 

This is more than just a story. It shows up “loud and clear” in their stellar Zen Ratings profile: 

Top 24% AI timeliness factor

Top 21% Growth

Top 20% Safety

Top 11% Value

Top 10% Sentiment

Not a single Component Grade is lower than top 30% (Financials). That well rounded goodness adds up to an elite A grade overall in the top 1.8% of all stocks we analyze. 

Wall Street is pounding the table too. That’s because all covering analysts give it a Strong Buy recommendation. 

The lowest target price calls for nearly 30% upside in the year ahead. Whereas the street high $19 points to greater than 50% gains in the year ahead. 

Yet if they keep up their beat and raise traditions of the past, then I think the future holds a likely doubling of these shares by the end of 2027. 

AMRX just might be the right prescription for your portfolio.  

What To Do Next?

Amneal Pharmaceuticals (AMRX) is just one of 20 stellar stocks found in my Zen Investor portfolio.

Each stock was selected by harnessing the power of the Zen Ratings along with my 45 years of successful investing experience. 

This dynamic combination has me pinpointing stocks with the unique opportunity to double or more in the next 1-2 years. 

The only way to see all these top 20 stocks is to become a Zen Investor member. 

Gladly that is a fairly easy process and right now you could save 50% on the subscription price. Just click below to…

Discover the Zen Investor & Top 20 Stocks Now > 

Wishing you a world of investment success!

Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)

Editor of the Zen Investor

Want to get in touch? Email us at news@wallstreetzen.com.